Darin Falk

Company: Lacerta Therapeutics, Inc.

Job title: Chief Scientific Officer

Bio:

Dr. Falk brings over 15 years of experience in AAV gene therapy with expertise in therapeutic development for neurodegenerative, neuromuscular and cardiovascular related indications. 

Seminars:

Improved AAV Vector Design to Manage Systemic Toxicity & Immunogenicity 11:05 am

Determining which vector components trigger liver toxicity and immune responses Capsid and payload optimization strategies to reduce toxicity and immunogenicity Understanding the latest tissue targeting and de-targeting vector design approaches to evade the liver Tissue tropism considerations for choosing a route of administration Levelling up characterisation and tissue tropism validation of novel vectorsRead more

day: PRE-CONFERENCE WORKSHOP DAY

Cassette Engineering to Improve Safety & Expression Profiles 8:30 am

Promoter optimization to accommodate genome size and expression profile Incorporation of regulatory elements to avoid over-expression related toxicity Strategies to predict activity and promote translational outcomes following cassette optimizationRead more

day: Conference Day Two